Citalopram, Serum
Citalopram is one of the selective serotonin reuptake inhibitors typically known as SSRIs, and belong to the class of drugs known as antidepressants. The SSRIs have become the first-line pharmaceutical treatment of depression in the United States and treat depression by increasing serotonergic activity. Other clinical uses of antidepressants are for disorders or clinical conditions such as obsessive-compulsive disorder, chronic pain, eating disorders, anxiety or panic disorders, peptic ulcer disease or childhood enuresis. The SSRIs typically do not elicit the anticholinergic side effects of the TCAs, are easier to tolerate, are not as toxic, and are safer for the patient. As occurs with most drugs, there are some side effects of SSRI use including anxiety, sleep disturbances, sexual dysfunction, and insomnia.
The SSRIs are lipophilic, have large volumes of distribution, well absorbed in the gastrointestinal tract, and reach peak plasma concentrations within one to eight hours. Most SSRIs are metabolized by the cytochrome P450 system and many of the metabolites are pharmacologically active. Citalopram is metabolized to desmethylcitalopram, which is also pharmacologically active. The half-lives of these particular drugs are quite variable. The half-live of citalopram is between 24-48 hours (average 35 hours). SSRI plasma concentrations are not routinely measured because they have not been show to correlate with clinical response.
The effects associated with citalopram abuse include hallucinations, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.
In conclusion, SSRIs, including citalopram, are frequently prescribed and therefore.
- Drug abuse evaluation
- Toxicity assessment
- Patient Compliance
- Potential identification of rapid metabolizers
Therapeutic concentration in blood: variable
Toxic concentration: variable
Fatal concentration: variable
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values are generally used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as IA, or a quantitative method such as GC/MS or LC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.
Stability
- Ambient: 5 days
- Refrigeration: 7 days
- Frozen: 30 days
- Antidepressant DEA Drug Fact Sheet.
- Levine, Barry (Ed). Therapeutic Drugs II: Antidepressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 403-420.
- Balant-Georgia AE, Balant LP. Milestones in clinical pharmacology. Therapeutic drug monitoring of antidepressants. Clin Ther. 1992;14(4):612-4.
- Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
- Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
- Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
- Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
- Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6